Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.
Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.
Wells Fargo rates Design Therapeutics overweight, citing DT-216P2’s RESTORE-FA data and best-in-disease potential vs Skyclarys. Read more here.
An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.
This is the newest page. Registered accounts read further back.